Estradiol treatment altered anticholinergic-related brain activation during working memory in postmenopausal women.

Dumas JA, Kutz AM, Naylor MR, Johnson JV, Newhouse PA
Neuroimage. 2012 60 (2): 1394-403

PMID: 22266175 · PMCID: PMC3303937 · DOI:10.1016/j.neuroimage.2012.01.043

Estradiol has been shown to affect cholinergic modulation of cognition in human and nonhuman animal models. This study examined the brain-based interaction of estradiol treatment and anticholinergic challenge in postmenopausal women during the performance of a working memory task and functional MRI. Twenty-four postmenopausal women were randomly and blindly placed on 1mg oral 17-β estradiol or matching placebo pills for three months after which they participated in three anticholinergic challenge sessions. During the challenge sessions, subjects were administered the antimuscarinic drug scopolamine, the antinicotinic drug mecamylamine, or placebo. After drug administration, subjects completed an fMRI session during which time they performed a visual verbal N-back test of working memory. Results showed that scopolamine increased activation in the left medial frontal gyrus (BA 10) and mecamylamine increased activation in the left inferior frontal gyrus (BA 46). Estradiol treatment compared to placebo treatment significantly reduced the activation in this left medial frontal region during scopolamine challenge. Estradiol treatment also increased activation in the precuneus (BA 31) during mecamylamine challenge. These data are the first to show that estradiol modulated antimuscarinic- and anitnicotinic-induced brain activity and suggest that estradiol affected cholinergic system regulation of cognition-related brain activation in humans.

Copyright © 2012 Elsevier Inc. All rights reserved.

MeSH Terms (11)

Aged Brain Cholinergic Fibers Double-Blind Method Estradiol Estrogens Female Humans Memory, Short-Term Middle Aged Postmenopause

Connections (1)

This publication is referenced by other Labnodes entities: